Company: BGLC
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001477932-25-008343
Chunk: 7

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 7
---
 September 30, 2025 *  1,796,597  $17,331,810  $(5,011,891) $(5,391,110) $(112,547) $6,816,262 

* Share activity (number of shares or both number and amount of shares) has been adjusted for the periods shown to reflect the 1-for-10 reverse stock split effected on April 7, 2025, on a retroactive basis 

# Rounding down of 169.30 fractional shares resulting from a 1-to-10 reverse stock split at a price of $2.98 per share

See accompanying notes to the condensed consolidated financial statements.

 8Table of Contents

BIONEXUS GENE LAB CORP. 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

  Nine months ended   September 30,   2025  2024 Cash flows from operating activities:      Net loss $(1,948,490) $(1,250,023)         Adjustments to reconcile net loss to net cash used in operating activities:        Amortization of right-of-use asset  41,666   35,507 Allowances for expected credit losses  215,942   122,843 Recoveries for expected credit losses  (94,912)  (842,401)Depreciation of property, plant and equipment  83,443   74,611 Dividend income  (21,752)  (59,653)Fair value loss/(gain) on investments in equity securities, net  91,243   (63,650)Loss arising from settlement of supplier contract dispute  -   29,140 Gain on disposal of investments in equity securities  (27,547)  (35,098)Loss on lease termination  -   (578)Operating loss before working capital changes  (1,660,407)  (1,989,302)         Changes in operating assets and liabilities:        Inventories  381,176   (251,306)Trade and other receiv